Expert-Led Discourse on Treatment Strategies for Advanced HER2-Negative Gastric/GEJ Cancers

Join us for a live virtual symposium and learn from the experts as they discuss current and emerging treatment options and recommendations for both previously untreated and treated HER2-negative gastric/GEJ cancers.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


7:00 PM   Welcome and Program Overview

7:05 PM   Initial Therapy for Previously Untreated HER2-Negative Gastric/GEJ Cancers –
                 Yelena Y. Janjigian, MD

- Current treatment options and recommendations
- Emerging therapy options

7:30 PM   Therapy for Previously Treated HER2-Negative Gastric/GEJ Cancers –
                 Samuel Klempner, MD

- Selection and sequencing of current treatment options
- Emerging therapy options

7:50 PM   Final Thoughts and Audience Question and Answer Session


Date / Time
Event Details


Yelena Y. Janjigian, MD

Associate Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Samuel Klempner, MD

Associate Professor
Division of Hematology-Oncology
Department of Medicine
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to guide selection of individualized treatments for patients with gastric/GEJ cancers.

Target Audience
This educational program is intended for medical oncologists, nurses, pharmacists, and other HCPs who treat patients with gastric/GEJ cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess clinical data on immunotherapies and new molecularly targeted agents for the treatment of advanced HER2-negative gastric/GEJ cancers
  • Incorporate newly approved immune checkpoint inhibitor-based combinations into the individualized management of advanced HER2-negative gastric cancer
  • Develop optimal sequencing of agents for second and subsequent lines in advanced HER2 negative gastric/GEJ cancer
  • Identify patients who may benefit from participation in ongoing clinical trials based on prior therapies, patient characteristics and preferences, and tumor characteristics


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-161-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.